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Pneumonia and ACE inhibitors—and cough
Too early to use ACE inhibitors to prevent pneumonia
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Angiotensin converting enzyme (ACE) inhibitors are widely
used to treat heart failure and hypertension. They act through
blocking the conversion of angiotensin I to angiotensin II; this
inhibits the breakdown of bradykinin, which in turn lowers
arteriole resistance and increases venous return. Many patients
taking ACE inhibitors experience a persistent dry cough, which
is thought to be caused by increased concentrations of
bradykinin; the cough is triggered by the endothelial effects of
bradykinin and other peptides. Refractory cough is the most
common reason for switching from ACE inhibitors to
angiotensin II receptor blockers (ARBs), which do not inhibit
the breakdown of kinins and are less likely to cause troublesome
coughing. In the linked study (doi:10.1136/bmj.e4260), Caldeira
and colleagues examined the risk of pneumonia with both classes
of drug, hypothesising that the cough associated with ACE
inhibitors might protective against pneumonia.1
Coughing is one of the most common reasons that patients
consult a primary care doctor, and it has a substantial effect on
quality of life. It also has a large economic impact—annual
expenditure on cough treatments is unknown because many are
over the counter preparations, but it is estimated to run into
millions of pounds in the United Kingdom. In patients taking
ACE inhibitors the chronic cough is associated with throat
irritation, and the only wholly effective way to prevent it is to
stop taking the drug.2 However coughing helps protect the
respiratory tree from aspiration of pharyngeal contents and
increases clearance of inhaled organisms. It therefore follows
that ACE inhibitors, but not ARBs, could protect against lower
respiratory tract infection, and this has been suggested by some
earlier trials.
Caldeira and colleagues studied this question by performing a
systematic review and meta-analysis of trials and studies of
ACE inhibitors and ARBs.1 Their review seems to support the
pharmacological and pathological hypothesis and suggests a
protective role for ACE inhibitors in reducing the incidence of
(and possibly mortality from) pneumonia.
The authors undoubtedly made stringent attempts to pool all
available data and undertook a thorough search of clinical
studies of ACE inhibitors and ARBs with few eligibility
restrictions. The review was not restricted to prospective
randomised controlled trials and included both retrospective
and prospective observational cohort and case-control studies.
Most data came from unpublished studies identified from a
search of regulatory documents placed on the Food and Drug
Administration website.
Respiratory infection was not a primary outcome in most of
these studies, and data were collected predominantly from
reporting of adverse events (in randomised controlled trials) or
from database coding for pneumonia or lower respiratory tract
infection (in observational studies). Pneumonia and lower
respiratory tract infections represent a heterogeneous group of
overlapping disorders with multiple causes and several different
ICD9/10 (international classification of diseases, 9th/10th
revision) and other codes.
Meta-analysis is a useful tool if the quality and evidence base
of the contributing studies is satisfactory. In this study, the
quality of reporting was assessed using several different tools,
and the results suggest a high risk of reporting bias, together
with substantial heterogeneity. This is explained by the variety
of study designs included, and it probably excludes further
quantitative and subgroup analysis.3The efficacy findings should
therefore be interpreted with caution.
It is unclear why, in the overall comparison of ACE inhibitors
and ARBs in preventing pneumonia, the effect was noted only
in the cohort and nested case-control studies and not in the
randomised trials. The analysis of randomised controlled trials
is probably more robust owing to the inherent bias in the design
of observational studies.
This does not mean an effect was not present, but it is difficult
to agree with the authors that “best evidence” points to ACE
inhibitors protecting against pneumonia. Is it right on the basis
of this study to recommend that patients should put up with
their resistant cough because it could reduce their risk of
pneumonia? This is an important clinical question, but to agree
would run counter to current evidence based guidelines that
recommend discontinuation.2 Extrapolation of results could lead
to serious misconceptions: could a smoker’s cough ever be
considered to confer a health benefit? Further studies are needed
and should include full health economic analyses and
investigation of alternative hypotheses. Immunomodulatory
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effects and a reduction in systemic cytokine responses have
been noted with ACE inhibitors,4 and improvements in
respiratory function with increases in exercise tolerance,
perfusion, and gas transfer have been reported.5 The ACE
inhibitor cough has been associated with a genetic variant of
the bradykinin B2 receptor promoter,6 and linkage to other genes
that influence susceptibility to infection is a possibility. A better
understanding of the pharmacological properties and effects of
these widely prescribed drugs is needed before we advise
patients to put up with their cough because it may prevent them
from getting pneumonia.
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